Wegovy Compared to Mounjaro: Which Medicine Fits Your Situation?

How the two medicines differ mechanically — and why it matters for results

Mounjaro works on both the GIP and GLP-1 receptors; Wegovy works on GLP-1 alone. That dual action appears to drive stronger average weight loss at the top of the dose range, though the gap between the two medicines has narrowed with the approval of Wegovy's 7.2 mg dose. In the SURMOUNT-5 open-label trial, published in the New England Journal of Medicine in 2025, tirzepatide produced greater average weight reduction than semaglutide 2.4 mg over 72 weeks in adults with obesity who did not have type 2 diabetes. At 7.2 mg, Wegovy trials reported around 20.7% average loss, which approaches tirzepatide's top-dose figures. If you want to understand how effective Wegovy is compared to Mounjaro across the full range of trial data, the evidence is worth reading in detail before drawing conclusions. So the straightforward claim that Mounjaro always outperforms Wegovy is less clear-cut than it once was.

What the trials do not tell you is which medicine will suit your individual physiology, medical history or tolerance. Nausea and other gastrointestinal effects are common with both, typically most noticeable after starting or a dose increase before settling. If you want a closer look at how Wegovy works compared to Mounjaro at the receptor level, that detail can help clarify why side-effect profiles differ between the two. The NHS tirzepatide patient information and the equivalent page for semaglutide set out the side-effect profiles in plain language for each.

Mounjaro is currently the only dual-agonist weight-loss medicine licensed in the UK. That distinction matters clinically for certain patients, though for others a single-pathway medicine works perfectly well. Which receptor combination suits you is not something a comparison article can answer.

Eligibility: where the two medicines actually diverge for UK patients

The private licensed eligibility criteria for both medicines are broadly similar: adults with a BMI of 30 or above, or 27 and above where at least one weight-related condition is present. Lower thresholds apply for some ethnic backgrounds under UK clinical guidance. BMI alone never seals the decision; the prescriber weighs the whole picture.

On the NHS, the routes are meaningfully different. NICE's appraisal of tirzepatide (TA1026) recommends it for adults with a BMI of 35 or above plus at least one qualifying comorbidity, within the NHS's phased rollout. NICE's recommendation for semaglutide (TA875) specifies use within a specialist weight management service for a maximum of two years. Both pathways come with waiting lists that many people find frustratingly long.

For patients considering a private route, the distinction between the two treatments comes down to clinical suitability rather than administrative criteria. A prescriber reviewing your consultation can factor in whether you've previously tried one of them, how you tolerated it, and what your medical history suggests about which mechanism is more appropriate. That's not a judgement a side-by-side article can make. You can read more about the effectiveness evidence in detail if you want to go deeper before your consultation.

Injection or tablet: a practical consideration many people overlook

Mounjaro is currently available only as a once-weekly injection. Wegovy now comes in two forms: the original injection pen and, as of June 2026, an oral tablet approved by the MHRA, the first oral GLP-1 medicine licensed in the UK for weight management. The Wegovy tablet is taken once daily, first thing in the morning on an empty stomach, at least 30 minutes before food or drink. No refrigeration is needed, which makes it a genuinely different practical option for people whose work or travel patterns make keeping a pen cold awkward.

The tablet's trial data (OASIS 4, 64 weeks) returned around 13.6% average weight loss regardless of adherence, and around 17% among participants who stayed fully adherent throughout. That adherence-dependent figure is worth understanding: the tablet requires a strict morning routine to achieve its best effect, and partial adherence blunts results more than with an injection. If you find daily routines easier to maintain than weekly injections, or needles are a barrier for you, this matters. If the opposite is true, it probably doesn't.

Our prescribers are familiar with patients who come in having already decided, and equally familiar with patients who are genuinely unsure. Either way, the consultation is the right place to land on a specific form. A thorough look at how Wegovy and Mounjaro compare across mechanism, form and results is worth working through before that conversation if you want to come in prepared.

Cost and what a legitimate price actually covers

Price is often the first thing people search for and the last thing that should drive the decision for a prescription medicine. That said, it is a real factor and deserves a straight answer.

UK private prices for weight-loss treatments vary by medicine, dose and provider. Since Eli Lilly raised Mounjaro's UK list price in September 2025, typical private prices have ranged roughly £149–£375 per month by dose and provider, as widely reported. Wegovy pricing sits in a broadly similar range depending on the dose and the form. Headlines can be misleading: a low-looking price may exclude consultation fees, prescription charges, delivery, or any clinical aftercare. It is worth checking what a quoted price actually includes before treating it as comparable.

If you want to see how the two medicines stack up on cost alongside their clinical differences, our Mounjaro vs Ozempic page gives useful context on how semaglutide-based treatments sit within the broader landscape of injectable weight-loss options. A full Mounjaro vs Wegovy comparison, including a detailed breakdown of pricing, covers this properly. At nume, one transparent price includes the consultation, prescription, treatment and next-working-day delivery, with priority aftercare seven days a week. We are not the cheapest option available. That is a deliberate choice: the clinical infrastructure that sits behind a safe, genuine supply chain has a cost. For a prescription-only medicine, a small saving on the headline price is not the measure that matters most.

If you are ready to find out which treatment a prescriber would recommend for you, check your eligibility with a free consultation. Our clinical team reviews every consultation personally, the same day.